E. Ohman J or Asset Management AB Acquires 1,861 Shares of Waters Corporation $WAT

E. Ohman J or Asset Management AB lifted its holdings in Waters Corporation (NYSE:WAT) by 73.7% during the 1st quarter, HoldingsChannel reports. The fund owned 4,385 shares of the medical instruments supplier’s stock after acquiring an additional 1,861 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Waters were worth $1,306,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Waters by 543.8% during the fourth quarter. SG Americas Securities LLC now owns 37,244 shares of the medical instruments supplier’s stock worth $14,146,000 after purchasing an additional 31,459 shares during the period. Mackenzie Financial Corp raised its position in shares of Waters by 12.2% in the third quarter. Mackenzie Financial Corp now owns 231,852 shares of the medical instruments supplier’s stock valued at $69,512,000 after buying an additional 25,182 shares in the last quarter. Banque Cantonale Vaudoise boosted its stake in shares of Waters by 329.0% in the fourth quarter. Banque Cantonale Vaudoise now owns 4,294 shares of the medical instruments supplier’s stock valued at $1,631,000 after buying an additional 3,293 shares during the period. Erste Asset Management GmbH boosted its stake in shares of Waters by 204.3% in the third quarter. Erste Asset Management GmbH now owns 14,301 shares of the medical instruments supplier’s stock valued at $4,155,000 after buying an additional 9,601 shares during the period. Finally, TD Asset Management Inc grew its position in Waters by 12.6% during the third quarter. TD Asset Management Inc now owns 250,024 shares of the medical instruments supplier’s stock worth $74,960,000 after buying an additional 27,990 shares in the last quarter. 94.01% of the stock is owned by institutional investors.

Waters Stock Performance

Shares of NYSE:WAT opened at $356.26 on Monday. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $414.15. The stock has a market capitalization of $34.98 billion, a price-to-earnings ratio of 45.27, a price-to-earnings-growth ratio of 2.15 and a beta of 1.21. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. The company’s 50 day simple moving average is $342.66 and its 200 day simple moving average is $348.22.

Waters (NYSE:WAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.31 by $0.39. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.The company’s quarterly revenue was up 91.4% on a year-over-year basis. During the same period in the prior year, the company earned $2.25 earnings per share. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, research analysts predict that Waters Corporation will post 14.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on WAT shares. JPMorgan Chase & Co. raised their price objective on Waters from $330.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th. Evercore upgraded Waters from an “in-line” rating to an “outperform” rating and set a $350.00 target price for the company in a research report on Monday, April 6th. TD Cowen increased their target price on Waters from $345.00 to $385.00 and gave the stock a “hold” rating in a report on Wednesday, May 6th. UBS Group raised their price target on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Finally, Robert W. Baird set a $387.00 price target on Waters in a research note on Wednesday, May 6th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $394.56.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.